NasdaqCM:BLPH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Bellerophon Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BLPH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.2%

BLPH

0.6%

US Medical Equipment

0.09%

US Market


1 Year Return

19.2%

BLPH

14.8%

US Medical Equipment

12.6%

US Market

Return vs Industry: BLPH exceeded the US Medical Equipment industry which returned 14.8% over the past year.

Return vs Market: BLPH exceeded the US Market which returned 12.6% over the past year.


Shareholder returns

BLPHIndustryMarket
7 Day7.2%0.6%0.09%
30 Day-10.8%0.9%-1.6%
90 Day-18.7%11.4%7.9%
1 Year19.2%19.2%15.8%14.8%15.2%12.6%
3 Year-37.1%-37.1%72.3%67.9%38.9%29.6%
5 Year-88.8%-88.8%148.2%129.3%87.6%66.5%

Price Volatility Vs. Market

How volatile is Bellerophon Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bellerophon Therapeutics undervalued compared to its fair value and its price relative to the market?

1.88x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BLPH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BLPH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BLPH is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: BLPH is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BLPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BLPH is good value based on its PB Ratio (1.9x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Bellerophon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

31.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLPH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BLPH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BLPH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if BLPH's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if BLPH's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BLPH's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Healthcare industry.

Past Performance

How has Bellerophon Therapeutics performed over the past 5 years?

29.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BLPH is currently unprofitable.

Growing Profit Margin: BLPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BLPH is unprofitable, but has reduced losses over the past 5 years at a rate of 29.8% per year.

Accelerating Growth: Unable to compare BLPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLPH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: BLPH has a negative Return on Equity (-32.13%), as it is currently unprofitable.


Next Steps

Financial Health

How is Bellerophon Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: BLPH's short term assets ($60.3M) exceed its short term liabilities ($6.6M).

Long Term Liabilities: BLPH's short term assets ($60.3M) exceed its long term liabilities ($2.7M).


Debt to Equity History and Analysis

Debt Level: BLPH is debt free.

Reducing Debt: BLPH has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BLPH has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BLPH has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 32.1% each year.


Next Steps

Dividend

What is Bellerophon Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BLPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLPH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Fabian Tenenbaum (46 yo)

3.83yrs

Tenure

US$1,399,996

Compensation

Mr. Fabian Tenenbaum, M.B.A, has been the Chief Executive Officer of Bellerophon Therapeutics, Inc. since November 2016. Mr. Tenenbaum served as Chief Financial Officer and Chief Business Officer of Beller ...


CEO Compensation Analysis

Compensation vs Market: Fabian's total compensation ($USD1.40M) is above average for companies of similar size in the US market ($USD589.17K).

Compensation vs Earnings: Fabian's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Fabian Tenenbaum
CEO & Director3.83yrsUS$1.40m0.29%
$ 287.1k
Assaf Korner
CFO & Secretary2.67yrsUS$488.41k0.046%
$ 46.6k
Peter Fernandes
Chief Regulatory & Safety Officer5.33yrsUS$533.98k0.13%
$ 128.3k
Parag Shah
Vice President of Business Operationsno datano data0.074%
$ 74.4k
Amy Edmonds
Vice President of Clinical Operations & Administration5yrsno data0.098%
$ 98.8k
Wassim Fares
Chief Medical Officer0.083yrno data0.042%
$ 42.3k

3.8yrs

Average Tenure

46yo

Average Age

Experienced Management: BLPH's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Fabian Tenenbaum
CEO & Director3.83yrsUS$1.40m0.29%
$ 287.1k
Naseem Amin
Independent Director5.25yrsUS$66.32k1.28%
$ 1.3m
Matthew Bennett
Independent Director2.5yrsUS$56.32k0.021%
$ 21.5k
Mary Cloyd
Independent Director4.58yrsUS$71.32k0.015%
$ 15.4k
Scott Bruder
Independent Director5.33yrsUS$56.32k0.013%
$ 13.2k
Jonathan Peacock
Chairman of the Board6.25yrsUS$200.00k1.39%
$ 1.4m
Andre Moura
Independent Director6.58yrsUS$61.32k0.062%
$ 62.5k
Theodore Wang
Independent Director2.83yrsUS$56.32k0.64%
$ 643.9k
Crispin Teufel
Independent Director1.5yrsUS$74.45k0%
$ 0

4.6yrs

Average Tenure

53yo

Average Age

Experienced Board: BLPH's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BLPH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 106.8%.


Top Shareholders

Company Information

Bellerophon Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bellerophon Therapeutics, Inc.
  • Ticker: BLPH
  • Exchange: NasdaqCM
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$100.392m
  • Shares outstanding: 9.50m
  • Website: https://www.bellerophon.com

Number of Employees


Location

  • Bellerophon Therapeutics, Inc.
  • 184 Liberty Corner Road
  • Suite 302
  • Warren
  • New Jersey
  • 7059
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLPHNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2015
6L7ADB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2015
0HMPLSE (London Stock Exchange)YesCommon StockGBUSDFeb 2015

Biography

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpul ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/20 06:07
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.